Skip to content
10-Q

Quarterly Report

NEVRO CORP.

0000950170-24-054685

← back to feed
Filed
May 7, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Apr 30, 2024 36.73M sh
Shares Diluted Q1 2024 · Mar 31, 2024 36.47M sh
Shares Diluted Q1 2024 · Mar 31, 2023 35.58M sh
Capex Q1 2024 · Mar 31, 2024 $2.79M
Capex Q1 2024 · Mar 31, 2023 $2.59M
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$32.66M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$29.31M
Long Term Debt Q1 2024 · Mar 31, 2024 $214.76M
Long Term Debt Q1 2024 · Dec 31, 2023 $211.47M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $90.3M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $104.22M
Stockholders Equity Q1 2024 · Mar 31, 2024 $278.54M
Stockholders Equity Q1 2024 · Dec 31, 2023 $293.15M
Stockholders Equity Q1 2024 · Mar 31, 2023 $301.23M
Stockholders Equity Q1 2024 · Dec 31, 2022 $323.88M
Current Liabilities Q1 2024 · Mar 31, 2024 $66.77M
Current Liabilities Q1 2024 · Dec 31, 2023 $83.38M
Total Liabilities Q1 2024 · Mar 31, 2024 $317.51M
Total Liabilities Q1 2024 · Dec 31, 2023 $342.57M
Current Assets Q1 2024 · Mar 31, 2024 $492.6M
Current Assets Q1 2024 · Dec 31, 2023 $530.92M
Total Assets Q1 2024 · Mar 31, 2024 $596.05M
Total Assets Q1 2024 · Dec 31, 2023 $635.71M
Eps Diluted Q1 2024 · Mar 31, 2024 −$0.70
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.98
Eps Basic Q1 2024 · Mar 31, 2024 −$0.70
Eps Basic Q1 2024 · Mar 31, 2023 −$0.98
Sga Expense Q1 2024 · Mar 31, 2024 $88.33M
Sga Expense Q1 2024 · Mar 31, 2023 $86.19M
Rd Expense Q1 2024 · Mar 31, 2024 $14.83M
Rd Expense Q1 2024 · Mar 31, 2023 $14.76M
Net Income Q1 2024 · Mar 31, 2024 −$25.41M
Net Income Q1 2024 · Mar 31, 2023 −$35.03M
Operating Income Q1 2024 · Mar 31, 2024 −$35.83M
Operating Income Q1 2024 · Mar 31, 2023 −$36.32M
Gross Profit Q1 2024 · Mar 31, 2024 $71.53M
Gross Profit Q1 2024 · Mar 31, 2023 $64.62M
Revenue Q1 2024 · Mar 31, 2024 $101.9M
Revenue Q1 2024 · Mar 31, 2023 $96.33M